MPS Pharmaa (531686)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Listed on Indian exchanges with a market cap of ₹7 crore, providing a small but tradeable microcap vehicle.
• Book value remains positive at ₹0.76 per share, offering some residual asset cover.
• The stock is at the top of its 52-week range of ₹1.57-₹3.66, suggesting recent buying interest.
• No debt-equity figure was given, so there is no immediate evidence of excessive borrowings in this data.

Concerns

• Latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr, implying no operating revenue.
• ROE of -61.46% and ROCE of -9.79% reflect severe value destruction and unprofitable capital use.
• Piotroski F-Score of 2/9 signals very weak financial health.
• At ₹3.66, the P/B of 4.82 is expensive compared to book value of ₹0.76, with zero earnings or dividend support.

AI Analysis

Let me start with the numbers that matter. MPS Pharmaa has no sales in the latest quarter, a net profit of zero, and a return on equity of -61.46%. In Buffett's language, this is a business that is destroying value, not creating it. A company that earns negative returns on shareholder capital cannot be valued on earnings; the P/E of 0.00 is meaningless. The Piotroski F-Score of 2 out of 9 tells me the financial position is weak. We don't have promoter holding or debt details, but the available figures are enough to make me reach for my pass card. Graham would look at book value of ₹0.76 per share. At ₹3.66, I am being asked to pay 4.82 times book for a business whose return on capital employed is -9.79%. That is not a margin of safety; that is a margin of optimism. The market cap is just ₹7 crore, so it is a microcap, but small size cannot make up for absent revenue and negative profitability. Profit growth has declined by 29.41%, and there is no dividend to compensate while waiting. The stock sits at the top of its 52-week range, but in value investing, price momentum is not a substitute for business quality. I cannot find a moat in this data. There is no sales growth, no earnings power, and no positive return on equity. Without a clear path to profitability, this is not a business I can analyze for intrinsic value. It may be a speculative vehicle for traders, but for an investor seeking safety and compounding, this fails every test on the worksheet. In Graham's words, the margin of safety must be demonstrated by numbers. Here, the numbers demonstrate the opposite. I would need to see meaningful revenue, improving margins, and a price closer to or below book before this could even enter my circle of competence.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer